Article - 05/04/2008 Successful cooperation between science and industry (II) In the second article in the series on the platforms successful cooperations BioValley presents an encouraging approach for improving the quality of life of severely ill cancer patients and the successful establishment of an industrial biochip platform. https://www.gesundheitsindustrie-bw.de/en/article/news/successful-cooperation-between-science-and-industry-ii
Article - 31/03/2008 "Nanomedicine will be able to combat incurable diseases" The first European Conference for Clinical Nanomedicine is to be held soon in Basel. BIOPRO has therefore discussed this promising area of application with Beat Löffler and Dr. Patrick Hunziker the founders of the European Foundation for Clinical Nanomedicine.https://www.gesundheitsindustrie-bw.de/en/article/news/nanomedicine-will-be-able-to-combat-incurable-diseases
Article - 16/03/2008 New indication for lead compound of Apogenix Isolated tumour cells use to invade healthy brain tissue during the development and growth of glioblastoma multiforme GBM. This mechanism involves the CD95CD95L death system. These results supports the therapeutic potential of Apogenix APG101 for the treatment of glioblastomas.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-indication-for-lead-compound-of-apogenix
Article - 28/02/2008 Gilbert Gorr - a great fan of the moss Physcomitrella patens Dr. Gilbert Gorr has been fascinated by the moss Physcomitrella patens for many years in fact it occupies a great deal of his waking moments. The enthusiasm with which the CSO of greenovation Biotech GmbH talks about the key object of his work is both intoxicating and contagious. The latest discovery The moss produces a therapeutic antibody that is far more effective than its predecessors created in animal cell cultures.https://www.gesundheitsindustrie-bw.de/en/article/news/gilbert-gorr-a-great-fan-of-the-moss-physcomitrella-patens
Press release - 25/02/2008 "Clinical Trials" junior researcher academy Young medical professionals or young scientists are eligible to apply for funding.https://www.gesundheitsindustrie-bw.de/en/article/press-release/clinical-trials-junior-researcher-academy
Article - 05/02/2008 Protecting the liver from oxygen stress The Emmy Noether junior research group in the Department of Surgery at the University Hospital of Heidelberg is to be funded with 1.2 million over the next five years. The group will focus on how tissue damage in donor livers can be prevented. The group headed by Dr. Martin Schneider.https://www.gesundheitsindustrie-bw.de/en/article/news/protecting-the-liver-from-oxygen-stress
Article - 15/01/2008 Female hearts fibrillate differently Gender-specific differences are currently not only a subject of debate for experts but have also raised broad media interest. However there are very few specific investigations that are able to provide a clear answer said Prof. Volker Kühlkamp chief physician in the Department of CardiologyElectrophysiology at the Lake Constance Heart Centre in ConstanceKreuzlingen and specialist in cardiac arrhythmia. https://www.gesundheitsindustrie-bw.de/en/article/news/female-hearts-fibrillate-differently
Press release - 15/01/2008 ALVESCO® gains FDA approval for the U.S. market The Food and Drug Administration approved Nycomeds ALVESCO ciclesonide Inhalation Aerosol in the United States for the maintenance treatment of asthma and as prophylactic therapy in adult and adolescent patients aged 12 years and older.https://www.gesundheitsindustrie-bw.de/en/article/press-release/alvesco-gains-fda-approval-for-the-u-s-market